口腔乾燥症治療薬の世界市場レポート 2025年

口腔乾燥症治療薬市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR5.3％で27億9,000万米ドルに成長します。予測期間の成長は、市場における費用対効果の高い薬剤の容易な入手、口腔衛生状態の有病率の増加、ヘルスケア従事者の意識の高まり、政府の取り組み、薬剤使用の増加に起因すると考えられます。予測期間の主な動向には、人工唾液と唾液代替品、技術の進歩と製品の革新、個別化医療と標的療法、遠隔医療と遠隔モニタリング、非侵襲的療法の台頭などがあります。

がん治療における化学療法の利用拡大が、今後の口腔乾燥症治療薬市場の拡大を牽引すると予測されます。がん治療の要である化学療法は、強力な薬剤を使用してがん細胞を狙い撃ちし、増殖を抑えることで患者の予後改善に大きく貢献します。口腔乾燥症治療薬には、唾液分泌促進薬や洗口剤など、口腔乾燥症状の緩和、唾液分泌の促進、味覚の改善を目的とした様々な治療法が含まれ、がん治療中の患者の適切な栄養補給と口腔内の快適性を促進します。例えば、2022年1月現在、米国国立がん研究所（National Cancer Institute）の報告によると、米国におけるがん生存者数は推定1,810万人で、全人口の5.4%を占めています。2032年には、この数は全世界で2,250万人に達すると予測されており、現在の推定値から24.4％増加することになります。したがって、がん管理における化学療法の採用が増加していることが、口腔乾燥症治療薬市場成長の主な促進要因となっています。

口腔乾燥症治療薬市場の主要企業は、ドライマウスを管理するための便利で効果的なソリューションに対する需要の高まりに対応するため、口腔スプレーのような患者に優しい非侵襲的な治療法の開発に注力しています。口腔スプレーは、口腔内の患部に的を絞って塗布することができ、必要な場所に潤いと潤滑を与えます。例えば、インドを拠点とする製薬会社Kファーマシューティカルズは2023年7月、口腔乾燥症としても知られるドライマウスを緩和するために設計された、臨床的に証明された経口スプレー、アクオラルを発売しました。口腔乾燥症は、薬物や病気によって引き起こされることがあり、不快感、咀嚼・嚥下困難、口腔の健康合併症を引き起こします。アクオラルは、口腔内に長期間持続する保護バリアを形成することで、最大6時間の持続的な緩和を提供し、水分の損失を抑え、快適性を高めます。頻繁な再塗布が必要な従来の水性治療とは異なり、アクオラルは特許取得済みの酸化グリセリントリエステル（OGT）を使用しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、新型コロナウイルス感染症、そして景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 口腔乾燥症治療における世界のPESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因要因）
• 最終用途産業の分析
• 世界の口腔乾燥症治療市場の成長率分析
• 世界の口腔乾燥症治療薬市場規模実績と成長, 2019-2024
• 口腔乾燥症治療薬の世界市場規模と成長予測, 2024-2029, 2034F
• 世界の口腔乾燥症治療薬の有効市場規模（TAM）

第6章 市場セグメンテーション

• 世界の口腔乾燥症治療市場（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• 人工唾液または唾液代替物
• 唾液分泌促進剤
• 世界の口腔乾燥症治療市場（流通チャネル別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• ドラッグストア
• 通信販売薬局
• ハイパーマーケットとスーパーマーケット
• エンドユーザー別口腔乾燥症治療薬の世界市場、実績と予測, 2019-2024, 2024-2029F, 2034F
• 成人用
• 小児科
• 世界の口腔乾燥症治療市場、人工唾液または唾液代替品の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 経口スプレー
• ゲル
• ロゼンジ
• マウスウォッシュ
• 世界の口腔乾燥症治療薬市場、唾液分泌促進剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 処方薬
• 市販薬（OTC）
• チューインガムとロゼンジ

第7章 地域別・国別分析

• 世界の口腔乾燥症治療市場（地域別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の口腔乾燥症治療市場（国別）、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 口腔乾燥症治療市場の競合情勢
• 口腔乾燥症治療市場における企業プロファイル
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 3M Company Overview, Products and Services, Strategy and Financial Analysis
  • GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
  • Colgate-Palmolive Company Overview, Products and Services, Strategy and Financial Analysis
  • Fresenius Kabi AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Sun Pharmaceutical Industries Ltd.
• Church & Dwight Co. Inc.
• Cipla Ltd.
• Hikma Pharmaceuticals PLC
• Lupin Limited
• Synedgen Inc.
• Sunstar Suisse S.A.
• Advanz Pharma Corp.
• Pharmascience Inc.
• Mission Pharmacal Company
• Dentaid Ltd.
• Cyclacel Pharmaceuticals Inc.
• Parnell Pharmaceuticals Holdings Ltd.
• Teva Pharmaceutical Industries Ltd.
• Forward Science Holding Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 2029年の口腔乾燥症治療市場- 最も新たな機会を提供する国
• 2029年の口腔乾燥症治療市場- 最も新たな機会を提供するセグメント
• 2029年の口腔乾燥症治療市場- 成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Xerostomia therapeutics encompass treatments and medications utilized to manage dry mouth, a condition characterized by reduced saliva production. These therapies aim to alleviate symptoms such as difficulty swallowing and tasting, as well as prevent dental issues.

The main types of xerostomia therapeutics include artificial saliva or saliva substitutes, and salivary stimulants. Artificial saliva or saliva substitutes are products specifically formulated to replicate the natural properties of saliva, providing lubrication, moisture, and protection to the oral tissues. They are distributed through various channels including hospital pharmacies, retail pharmacies, drug stores, mail order pharmacies, as well as hypermarkets and supermarkets, catering to both adult and pediatric end users.

The xerostomia therapeutics market research report is one of a series of new reports from The Business Research Company that provides xerostomia therapeutics market statistics, including xerostomia therapeutics industry global market size, regional shares, competitors with a xerostomia therapeutics market share, detailed xerostomia therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the xerostomia therapeutics industry. This xerostomia therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The xerostomia therapeutics market size has grown strongly in recent years. It will grow from $2.14 billion in 2024 to $2.26 billion in 2025 at a compound annual growth rate (CAGR) of 5.7%. The growth in the historic period can be attributed to increasing incidences of xerostomia in the geriatric population, research and development of efficient products for xerostomia, growing awareness about xerostomia-related products, increasing of medical conditions, and rising prevalence of chronic diseases.

The xerostomia therapeutics market size is expected to see strong growth in the next few years. It will grow to $2.79 billion in 2029 at a compound annual growth rate (CAGR) of 5.3%. The growth in the forecast period can be attributed to easy availability of cost-effective medications in the market, increased prevalence of oral health conditions, rising awareness among healthcare practitioners, government initiatives, and increased medication use. Major trends in the forecast period include artificial saliva and saliva substitutes, technological advancements and product innovations, personalized medicine and targeted therapies, telehealth and remote monitoring, and rise of non-invasive therapies.

The increasing utilization of chemotherapy in cancer care is anticipated to drive the expansion of the xerostomia therapeutics market in the future. Chemotherapy, a cornerstone of cancer treatment, employs potent medications to target and suppress the proliferation of cancer cells, contributing significantly to improved patient outcomes. Xerostomia therapeutics encompass various interventions such as saliva-stimulating medications and mouth rinses designed to alleviate dry mouth symptoms, enhance saliva production, and improve taste sensation, thereby facilitating proper nutrition and oral comfort for patients undergoing cancer treatment. For example, as of January 2022, the National Cancer Institute reported an estimated 18.1 million cancer survivors in the United States, constituting 5.4% of the total population. By 2032, this number is projected to reach 22.5 million worldwide, reflecting a 24.4% increase from current estimates. Hence, the rising adoption of chemotherapy in cancer management is a key driver behind the growth of the xerostomia therapeutics market.

Major companies in the xerostomia therapeutics market are focusing on developing patient-friendly, non-invasive treatments such as oral sprays to meet the growing demand for convenient and effective solutions for managing dry mouth. Oral sprays allow for targeted application to the affected areas of the mouth, providing moisture and lubrication where needed. For example, in July 2023, K Pharmaceuticals, an India-based pharmaceutical company, launched Aquoral, a clinically proven oral spray designed to relieve dry mouth, also known as xerostomia. This condition, which can result from medications or diseases, causes discomfort, difficulties in chewing and swallowing, and oral health complications. Aquoral provides up to six hours of sustainable relief by forming a long-lasting protective barrier over the oral cavity, reducing moisture loss and enhancing comfort. Unlike traditional aqueous-based treatments that require frequent reapplication, Aquoral uses patented Oxidized Glycerol Triesters (OGT), a plant-derived lipid-based technology that offers superior protection.

In June 2022, Eagle Pharmaceuticals Inc., a US-based pharmaceutical company, completed the acquisition of Acacia Pharma Group plc for $104 million. This strategic move positions Eagle Pharmaceuticals as a significant player in the xerostomia therapeutics market, enhancing its product portfolio, market access, research and development capabilities, and potential for synergies and operational efficiencies. Acacia Pharma Group plc, headquartered in the UK, specializes in the development and commercialization of products aimed at addressing xerostomia and related conditions.

Major companies operating in the xerostomia therapeutics market are Bayer AG, 3M Company, GlaxoSmithKline plc, Colgate-Palmolive Company, Fresenius Kabi AG, Sun Pharmaceutical Industries Ltd., Church & Dwight Co. Inc., Cipla Ltd., Hikma Pharmaceuticals PLC, Lupin Limited, Synedgen Inc., Sunstar Suisse S.A., Advanz Pharma Corp., Pharmascience Inc., Mission Pharmacal Company, Dentaid Ltd., Cyclacel Pharmaceuticals Inc., Parnell Pharmaceuticals Holdings Ltd., Teva Pharmaceutical Industries Ltd., Forward Science Holding Inc., ICPA Health Products Ltd., CCMed Ltd., Bio Cosmetics Laboratories S.L., Quest Products LLC, Acacia Pharma, Saliwell Limited, OraCoat, Oralieve UK Ltd., OraPharma Inc., OraVital Inc

North America was the largest region in the xerostomia therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the xerostomia therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the xerostomia therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The xerostomia therapeutics market consists of revenues earned by entities by providing services such as medical consultations, pharmacological assistance, dental care, patient education, support services, and research and development, all geared towards treating and managing dry mouth. The market value includes the value of related goods sold by the service provider or included within the service offering. The xerostomia therapeutics market also includes sales of oral moisturizers, dental products such as fluoride treatments and saliva-stimulating mouthwashes, and oral lubricants. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Xerostomia Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on xerostomia therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for xerostomia therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The xerostomia therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Artificial Saliva Or Saliva Substitutes; Salivary Stimulants
• 2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Drug Stores; Mail Order Pharmacies; Hypermarkets And Supermarkets
• 3) By End-User: Adult; Pediatric
• Subsegments:
• 1) By Artificial Saliva Or Saliva Substitutes: Oral Sprays; Gels; Lozenges; Mouthwashes
• 2) By Salivary Stimulants: Prescription Drugs; Over-The-Counter (Otc) Products; Chewing Gums And Lozenges
• Companies Mentioned: Bayer AG; 3M Company; GlaxoSmithKline plc; Colgate-Palmolive Company; Fresenius Kabi AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Xerostomia Therapeutic Market Characteristics

3. Xerostomia Therapeutic Market Trends And Strategies

4. Xerostomia Therapeutic Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Xerostomia Therapeutic Growth Analysis And Strategic Analysis Framework

• 5.1. Global Xerostomia Therapeutic PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Xerostomia Therapeutic Market Growth Rate Analysis
• 5.4. Global Xerostomia Therapeutic Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Xerostomia Therapeutic Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Xerostomia Therapeutic Total Addressable Market (TAM)

6. Xerostomia Therapeutic Market Segmentation

• 6.1. Global Xerostomia Therapeutic Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Artificial Saliva Or Saliva Substitutes
• Salivary Stimulants
• 6.2. Global Xerostomia Therapeutic Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Drug Stores
• Mail Order Pharmacies
• Hypermarkets And Supermarkets
• 6.3. Global Xerostomia Therapeutic Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Adult
• Pediatric
• 6.4. Global Xerostomia Therapeutic Market, Sub-Segmentation Of Artificial Saliva Or Saliva Substitutes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral Sprays
• Gels
• Lozenges
• Mouthwashes
• 6.5. Global Xerostomia Therapeutic Market, Sub-Segmentation Of Salivary Stimulants, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Prescription Drugs
• Over-The-Counter (Otc) Products
• Chewing Gums And Lozenges

7. Xerostomia Therapeutic Market Regional And Country Analysis

• 7.1. Global Xerostomia Therapeutic Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Xerostomia Therapeutic Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Xerostomia Therapeutic Market

• 8.1. Asia-Pacific Xerostomia Therapeutic Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Xerostomia Therapeutic Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Xerostomia Therapeutic Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Xerostomia Therapeutic Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Xerostomia Therapeutic Market

• 9.1. China Xerostomia Therapeutic Market Overview
• 9.2. China Xerostomia Therapeutic Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Xerostomia Therapeutic Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Xerostomia Therapeutic Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Xerostomia Therapeutic Market

• 10.1. India Xerostomia Therapeutic Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Xerostomia Therapeutic Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Xerostomia Therapeutic Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Xerostomia Therapeutic Market

• 11.1. Japan Xerostomia Therapeutic Market Overview
• 11.2. Japan Xerostomia Therapeutic Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Xerostomia Therapeutic Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Xerostomia Therapeutic Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Xerostomia Therapeutic Market

• 12.1. Australia Xerostomia Therapeutic Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Xerostomia Therapeutic Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Xerostomia Therapeutic Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Xerostomia Therapeutic Market

• 13.1. Indonesia Xerostomia Therapeutic Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Xerostomia Therapeutic Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Xerostomia Therapeutic Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Xerostomia Therapeutic Market

• 14.1. South Korea Xerostomia Therapeutic Market Overview
• 14.2. South Korea Xerostomia Therapeutic Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Xerostomia Therapeutic Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Xerostomia Therapeutic Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Xerostomia Therapeutic Market

• 15.1. Western Europe Xerostomia Therapeutic Market Overview
• 15.2. Western Europe Xerostomia Therapeutic Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Xerostomia Therapeutic Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Xerostomia Therapeutic Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Xerostomia Therapeutic Market

• 16.1. UK Xerostomia Therapeutic Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Xerostomia Therapeutic Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Xerostomia Therapeutic Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Xerostomia Therapeutic Market

• 17.1. Germany Xerostomia Therapeutic Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Xerostomia Therapeutic Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Xerostomia Therapeutic Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Xerostomia Therapeutic Market

• 18.1. France Xerostomia Therapeutic Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Xerostomia Therapeutic Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Xerostomia Therapeutic Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Xerostomia Therapeutic Market

• 19.1. Italy Xerostomia Therapeutic Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Xerostomia Therapeutic Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Xerostomia Therapeutic Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Xerostomia Therapeutic Market

• 20.1. Spain Xerostomia Therapeutic Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Xerostomia Therapeutic Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Xerostomia Therapeutic Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Xerostomia Therapeutic Market

• 21.1. Eastern Europe Xerostomia Therapeutic Market Overview
• 21.2. Eastern Europe Xerostomia Therapeutic Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Xerostomia Therapeutic Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Xerostomia Therapeutic Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Xerostomia Therapeutic Market

• 22.1. Russia Xerostomia Therapeutic Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Xerostomia Therapeutic Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Xerostomia Therapeutic Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Xerostomia Therapeutic Market

• 23.1. North America Xerostomia Therapeutic Market Overview
• 23.2. North America Xerostomia Therapeutic Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Xerostomia Therapeutic Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Xerostomia Therapeutic Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Xerostomia Therapeutic Market

• 24.1. USA Xerostomia Therapeutic Market Overview
• 24.2. USA Xerostomia Therapeutic Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Xerostomia Therapeutic Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Xerostomia Therapeutic Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Xerostomia Therapeutic Market

• 25.1. Canada Xerostomia Therapeutic Market Overview
• 25.2. Canada Xerostomia Therapeutic Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Xerostomia Therapeutic Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Xerostomia Therapeutic Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Xerostomia Therapeutic Market

• 26.1. South America Xerostomia Therapeutic Market Overview
• 26.2. South America Xerostomia Therapeutic Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Xerostomia Therapeutic Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Xerostomia Therapeutic Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Xerostomia Therapeutic Market

• 27.1. Brazil Xerostomia Therapeutic Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Xerostomia Therapeutic Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Xerostomia Therapeutic Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Xerostomia Therapeutic Market

• 28.1. Middle East Xerostomia Therapeutic Market Overview
• 28.2. Middle East Xerostomia Therapeutic Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Xerostomia Therapeutic Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Xerostomia Therapeutic Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Xerostomia Therapeutic Market

• 29.1. Africa Xerostomia Therapeutic Market Overview
• 29.2. Africa Xerostomia Therapeutic Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Xerostomia Therapeutic Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Xerostomia Therapeutic Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Xerostomia Therapeutic Market Competitive Landscape And Company Profiles

• 30.1. Xerostomia Therapeutic Market Competitive Landscape
• 30.2. Xerostomia Therapeutic Market Company Profiles
  • 30.2.1. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. 3M Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Colgate-Palmolive Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Fresenius Kabi AG Overview, Products and Services, Strategy and Financial Analysis

31. Xerostomia Therapeutic Market Other Major And Innovative Companies

• 31.1. Sun Pharmaceutical Industries Ltd.
• 31.2. Church & Dwight Co. Inc.
• 31.3. Cipla Ltd.
• 31.4. Hikma Pharmaceuticals PLC
• 31.5. Lupin Limited
• 31.6. Synedgen Inc.
• 31.7. Sunstar Suisse S.A.
• 31.8. Advanz Pharma Corp.
• 31.9. Pharmascience Inc.
• 31.10. Mission Pharmacal Company
• 31.11. Dentaid Ltd.
• 31.12. Cyclacel Pharmaceuticals Inc.
• 31.13. Parnell Pharmaceuticals Holdings Ltd.
• 31.14. Teva Pharmaceutical Industries Ltd.
• 31.15. Forward Science Holding Inc.

32. Global Xerostomia Therapeutic Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Xerostomia Therapeutic Market

34. Recent Developments In The Xerostomia Therapeutic Market

35. Xerostomia Therapeutic Market High Potential Countries, Segments and Strategies

• 35.1 Xerostomia Therapeutic Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Xerostomia Therapeutic Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Xerostomia Therapeutic Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer